Educational Objectives Metastatic Breast Cancer: Scope of the Problem

Educational Objectives

Metastatic Breast Cancer: Scope of the Problem

Metastatic Breast Cancer: General Treatment Considerations

Therapeutic Goals/Endpoints in MBC

MBC: Impact of Chemotherapy

Treatment Options for Advanced Breast Cancer

First-Line Chemotherapy Options

Response Rates with Single-AgentChemotherapeutic Agents in MBC

Highlights of the Evolution of Taxanes in Oncology

Taxanes in the Treatment of MBC

Conventional Taxanes: Pharmacologic and

Pharmacodynamic Differences

Conventional Taxanes: Impact of Solvents

Albumin Role: Natural Carrier ofHydrophobic Molecules in Humans

Increased Intratumoral Concentration With nab-Paclitaxel

Differentiating the Taxanes: Toxicity

Making Taxanes Less “Tax-ing”

Taxane Toxicities

Randomized Comparison Between Taxanes

Taxanes: Premedication Guidelines

Taxane Hypersensitivity Reactions

Anemia

Differentiating the Taxanes: Efficacy

Pivotal Phase III Trials of PaclitaxelSingle Agent and Combinations

Pivotal Phase III Trials of DocetaxelSingle Agent and Combinations

TAX 311: Paclitaxel versus Docetaxel in Metastatic Breast

Cancer

TAX 311: Paclitaxel Versus Docetaxel in Metastatic Breast

Cancer – OS

TAX 311: Hematologic Toxicity

TAX 311: Non-Hematologic Toxicity

TAX 311: Quality of Life Analysis

Phase III Trial of nab-Paclitaxel vs Paclitaxel in MBC: Design

Phase III Trial of nab-Paclitaxel vs Paclitaxel in MBC: Results

Phase III Trial of nab-Paclitaxel vs Paclitaxel in MBC: TTP

Phase III Trial of nab-Paclitaxel vs Paclitaxel in MBC: OS

Phase III Trial of nab-Paclitaxel vs Paclitaxel in MBC: OS ( ≥ 2nd-line

Patients)

nab-Paclitaxel vs Paclitaxel in MBC: Hematologic Toxicities

nab-Paclitaxel vs Paclitaxel in MBC: Non-Hematologic Toxicities

nab-Paclitaxel vs Paclitaxel in MBC: Neuropathy Resolution

Phase II Study of Weekly nab-Paclitaxel in Taxane-Refractory

MBC

Taxanes: Cost-effectiveness Model

Cost-effectiveness Model: Methodology (cont.)

Costs per Cycle

Frequency of Grade 3/4 Toxicities (O’Shaughnessy 2003)

Treatment Costs per Toxicity for Taxane Therapy

Cost-effectiveness Ratios

Model Analysis of Total Costs

Conclusions